Results 181 to 190 of about 65,035 (206)

Ribavirin

2009
Jim Bellows, Robert Harrison, William Charney, Kevin Corkery, Lee Wugofski   +4 more
openaire   +2 more sources

Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

Lancet, The, 1998
Anders Sönnerborg
exaly  

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Lancet, The, 1998
Samuel S Lee, Vincent Bain, T Poynard
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Lancet, The, 2010
Paul Y Kwo, John M Vierling
exaly  

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Lancet, The, 2014
Gregory J Dore, Graham R Foster, Michael W Fried   +2 more
exaly  

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

Lancet, The, 2015
jean-michel Molina, Chloe Orkin, Mark Nelson   +2 more
exaly  

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly  

Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa

Lancet, The, 2000
Stanislas Pol
exaly  

Ribavirin

Reactions Weekly, 2002
openaire   +1 more source